Risk assessment for drug degradation products using physiologically-based pharmacokinetic models

[1]  J. Wilson,et al.  Surface area of the small intestine in man. , 1967, Gut.

[2]  J. Bridges,et al.  Metabolism of aniline in rats, pigs and sheep. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[3]  Joop L. M. Hermens,et al.  Determination of octanol/water partition coefficients for hydrophobic organic chemicals with the “slow‐stirring” method , 1989 .

[4]  D. Jollow,et al.  Use of the NIH shift to determine the relative contribution of competing pathways of aniline metabolism in the rat. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[5]  Harvey J Clewell,et al.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.

[6]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[7]  van Boris Wessel Schooten,et al.  Development and Specification of Virtual Environments , 2003 .

[8]  D. K. Gerken,et al.  Toxicity of p-chloroaniline in rats and mice. , 1990, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  George Loizou,et al.  Physiologically based pharmacokinetic modelling , 2003 .

[10]  Virunya S Bhat,et al.  Establishing a total allowable concentration of o-toluidine in drinking water incorporating early lifestage exposure and susceptibility. , 2012, Regulatory toxicology and pharmacology : RTP.

[11]  J. Popp,et al.  Perspectives on the mechanism of action of the splenic toxicity of aniline and structurally-related compounds. , 1987, Food and Chemical Toxicology.

[12]  Poul Thirup,et al.  Haematocrit: within-subject and seasonal variation. , 2003, Sports medicine.

[13]  R. Billings,et al.  Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes. A system in which the spatial organization inherent in the liver is disrupted. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[14]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[15]  R. R. Levine.  Factors affecting gastrointestinal absorption of drugs , 1970, The American Journal of Digestive Diseases.

[16]  J. H. Harrison,et al.  Contribution of aniline metabolites to aniline-induced methemoglobinemia. , 1987, Molecular pharmacology.

[17]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[18]  K. Pang.  Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J. Gastwirth.  Statistical Measures of Earnings Differentials , 1975 .

[20]  J. H. Harrison,et al.  Role of aniline metabolites in aniline-induced hemolytic anemia. , 1986, The Journal of pharmacology and experimental therapeutics.

[21]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[22]  Malcolm Rowland,et al.  Tissue lipids and drug distribution: dog versus rat. , 2012, Journal of pharmaceutical sciences.

[23]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[24]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.